Nasdaq25d
Greenwich LifeSciences Receives EMA Approval for Expanded Clinical Trial Sites in Europe for FLAMINGO-01 Study
Greenwich LifeSciences, Inc. announced progress in its Phase III clinical trial FLAMINGO-01, which is studying its immunotherapy GLSI-100 to prevent breast cancer recurrences. The European ...
Nasdaq25d
Greenwich LifeSciences Adds New Clinical Sites For FLAMINGO-01 Trial In Europe
(RTTNews) - Greenwich LifeSciences, Inc. (GLSI), a clinical-stage biopharmaceutical company, on Wednesday, announced that its application seeking expansion of its FLAMINGO-01 clinical trial in ...
Hosted on MSN1mon
Flamingo Transworld Announces Exciting Europe Summer 2025 Tours
Flamingo Transworld, Gujarat's leading international tour operator, renowned for curating exceptional vegetarian travel experiences, is thrilled to announce the launch of its much-awaited Europe ...
Business Insider25d
Greenwich LifeSciences Approved to Add Additional Sites to FLAMINGO-01 in Europe
The expansion of FLAMINGO-01 into Europe has been complimentary to the activated sites in the US, which also increased in 2024. In total we now have approximately 100 sites globally that are ...